Cancer Cost-shifting Provokes Discrimination Complaints
Exchange insurance plans may make second-class citizens of patients with chronic disease, a recent Peter Pitts commentary contends.
“Healthy Body, Healthy Mind” Educates on Pain Management
Public television viewers around the country can tune in this month for “Learning About Pain Management,” an episode of the long-running Healthy Body, Healthy Mind series.
Biologics Prescribers to FDA: Biosimilars Need Distinct Names
A group of specialty physician societies and members of AfPA’s National Physicians Biologics Working Group made a collective appeal to the Food and Drug Administration today for giving biosimilar follow-ons distinct names.
House Bill Clarifies Rules of Pain Pill Diversion and Patient Access
A bill recently passed in the U.S. House of Representatives could help members of the prescription drug supply chain comply with controlled substances law – and ensure patients access to the medications they need.
Biosimilar Naming, Extrapolation Pose Tough Questions for FDA
The FDA’s first biosimilar approval application has stirred high hopes among some members of the health care community – and heated debate among others.
The Real Value of Real-world Data
Real world data (RWD) provides valuable insight for improving health care, a new report from the Galen Institute contends.
Rx Response Maintains Access Amid Natural Disasters
Natural disasters can leave community members scrambling for shelter, clean water, food – and their prescription medications.
New Guidelines Put Preemies at Risk
The American Academy of Pediatrics’ new guidelines on RSV treatment, announced yesterday, sparked immediate and ardent debate, pitting premature babies’ families and care providers against the AAP in a showdown about who deserves preventative care.
In the Name of Patient Safety: Why Biosimilars Need Distinct Identifiers
An opponent to distinct names for biosimilar medications has petitioned the Food and Drug Administration with a new argument: Same old, same old works just fine.
Faster Cures Begin in the “Consortium Sandbox”
For patients waiting on medical advances to improve their lives, public-private research partnerships may present a more efficient alternative to traditional research.
